Dyslipidemia is a common finding in human patients with IBD and it can be attributed to the elevation of inflammatory cytokines such as TNF-α, interferon C, and interleukin-1 that inhibit lipoprotein lipase activity [30,31]. Here, LPL is linked to inflammatory bowel disease.